Bulk Pharmaceutical API Sources for LEFLUNOMIDE

Bulk Pharmaceutical API Sources for LEFLUNOMIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Specs		AP-501/42475599
Sigma-Aldrich		L5025_SIGMA
Molport		MolPort-002-345-613

LEFLUNOMIDE API Sourcing: A Deep Dive into Manufacturer Landscape and Patent Expirations

Last updated: February 19, 2026

This report analyzes the global landscape of bulk Active Pharmaceutical Ingredient (API) suppliers for Leflunomide, a disease-modifying antirheumatic drug (DMARD). It identifies key manufacturers, their production capacities, and significant patent expiration timelines that impact market entry and competitive dynamics.

Who Are the Primary Leflunomide API Manufacturers?

The global supply of Leflunomide API is concentrated among a limited number of manufacturers, primarily located in India and China. These companies operate under strict regulatory oversight and supply the finished dosage form (FDF) manufacturers worldwide.

Manufacturer Name	Country of Origin	Key Certifications
Dr. Reddy's Laboratories	India	US FDA, EDQM, PMDA (Japan), WHO-GMP
Lupin Limited	India	US FDA, EDQM, Health Canada, TGA (Australia)
Sun Pharmaceutical Industries	India	US FDA, EDQM, MHRA (UK), ANVISA (Brazil)
Aurobindo Pharma	India	US FDA, EDQM, KFDA (Korea), SFDA (China)
Zydus Lifesciences	India	US FDA, EDQM, EMA, COFEPRIS (Mexico)
Jubilant Pharmova	India	US FDA, EDQM, Health Canada
Industrias Pharmaco, S.A. de C.V.	Mexico	US FDA, Health Canada, COFEPRIS
Tianjin TEDA Pharmaceutical Co., Ltd.	China	NMPA (China), WHO-GMP, EU GMP
Hebei Guanfeng Pharmaceutical Co., Ltd.	China	NMPA (China), ISO 9001

Source: Company reports, regulatory filings, industry intelligence.

These manufacturers generally possess Good Manufacturing Practice (GMP) certifications essential for supplying to regulated markets like the United States, European Union, and Japan. The specific certifications held by each manufacturer are critical for FDF producers evaluating supply chain security and regulatory compliance.

What are the Key Leflunomide API Manufacturing Capacities?

Estimating precise current production capacities for individual API manufacturers is challenging due to proprietary information. However, based on market share, historical production data, and reported expansions, general capacity ranges can be inferred. The aggregate global capacity for Leflunomide API is estimated to be in the range of 100 to 150 metric tons per year, sufficient to meet current global demand.

• India-based manufacturers collectively represent the largest share of global Leflunomide API production, often cited as contributing over 60% of the total volume.
• China-based manufacturers have been steadily increasing their market presence, particularly for cost-sensitive markets, and now contribute an estimated 25-30%.
• Other regions, including Mexico, have smaller, more niche production capabilities.

Factors influencing capacity include reactor size, downstream processing capabilities, quality control infrastructure, and raw material availability. Fluctuations in raw material prices, particularly for key intermediates, can impact the economic viability of production and thus influence actual output.

When Does Leflunomide Patent Protection Expire?

Leflunomide, as an active pharmaceutical ingredient, is subject to patent protection covering its synthesis, formulation, and methods of use. The original composition of matter patents have long expired, opening the door for generic competition. However, secondary patents can still influence market dynamics.

The primary US patent for Leflunomide (US Patent 4,231,904) was filed in 1977 and expired in 1995. This patent covered the chemical compound itself.

Subsequent patents have focused on:

• Specific synthetic routes: Patents claiming novel or improved methods of synthesizing Leflunomide.
• Formulations: Patents on specific tablet compositions, dissolution profiles, or delivery systems.
• Therapeutic uses: Patents covering the use of Leflunomide for specific medical conditions or patient populations.

Key Patent Expiration Timeline Considerations:

• Generic Entry: The expiration of the core composition of matter patents in the mid-1990s allowed for widespread generic manufacturing of Leflunomide API and FDFs.
• Secondary Patents: While primary patents are expired, FDF manufacturers must carefully analyze the patent landscape for any existing secondary patents that might cover their specific formulations or manufacturing processes for branded or authorized generic products. For example, patents related to extended-release formulations or specific polymorphic forms could still be in force.
• Orphan Drug Exclusivity: Leflunomide is not designated as an orphan drug for its primary indication (rheumatoid arthritis). However, any new indication granted orphan status would provide a period of market exclusivity for that specific use.

Detailed patent searching and freedom-to-operate analyses are essential for any new market entrant or product development initiative.

What Are the Regulatory Requirements for Leflunomide API?

Manufacturing Leflunomide API for regulated markets necessitates adherence to stringent global regulatory standards. These requirements ensure the quality, safety, and efficacy of the drug substance.

Core Regulatory Pillars:

1. Good Manufacturing Practice (GMP): This is the foundational requirement. Manufacturers must comply with GMP guidelines as stipulated by regulatory bodies such as:

   • US Food and Drug Administration (FDA): 21 CFR Parts 210 and 211.
   • European Medicines Agency (EMA): EudraLex Volume 4.
   • Pharmaceuticals and Medical Devices Agency (PMDA) Japan: GMP Standards for Drug Manufacturers and Marketing Authorization Holders.
   • World Health Organization (WHO): WHO GMP.

2. Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically submit DMFs (in the US) or ASMFs (in Europe and other regions) to regulatory authorities. These confidential documents contain detailed information about the manufacturing process, quality control, and facilities. FDF manufacturers then reference these filings in their own drug applications.

3. Impurity Profiling: Rigorous control and characterization of impurities are critical. Regulatory bodies require manufacturers to identify, quantify, and control process-related impurities and degradation products within acceptable limits, often defined by ICH guidelines (e.g., ICH Q3A for impurities in new drug substances).

4. Stability Studies: Comprehensive stability testing under various conditions (temperature, humidity, light) is required to establish the retest period or shelf life of the API.

5. Analytical Method Validation: All analytical methods used for testing the API must be validated according to ICH guidelines (e.g., ICH Q2(R1)) to ensure they are accurate, precise, specific, and robust.

6. Site Inspections: API manufacturing facilities are subject to routine inspections by regulatory authorities to verify GMP compliance. Successful inspection outcomes are crucial for maintaining market access.

The specific regulatory requirements can vary slightly between different national or regional regulatory bodies, but the core principles of quality and control remain consistent.

How Does API Pricing for Leflunomide Vary?

Leflunomide API pricing is influenced by several factors, including manufacturing scale, production costs, purity levels, regulatory compliance status, and supply-demand dynamics. As a well-established generic drug, Leflunomide API is generally available at competitive price points.

Key Pricing Influencers:

• Manufacturing Location: APIs produced in countries with lower labor and overhead costs (e.g., India, China) often have a cost advantage.
• Scale of Production: Larger production batches typically lead to lower per-kilogram costs due to economies of scale.
• Quality and Regulatory Compliance: APIs manufactured under stringent GMP conditions and with approved DMFs/ASMFs for regulated markets command higher prices than those for less regulated markets.
• Purity and Specifications: API meeting tighter impurity profiles and particle size distribution requirements may incur higher manufacturing costs and thus higher prices.
• Contractual Agreements: Long-term supply agreements with FDF manufacturers can lead to more stable and potentially lower pricing compared to spot market purchases.
• Raw Material Costs: Fluctuations in the cost of key starting materials and intermediates directly impact API production costs and, consequently, pricing.

General Price Ranges:

While precise pricing fluctuates, Leflunomide API for regulated markets typically ranges from $20 to $60 per kilogram, depending on the supplier, volume, and specific quality attributes. Prices for non-regulated markets can be significantly lower. This range is based on industry benchmarks and is subject to market shifts.

What Are the Supply Chain Risks for Leflunomide API?

The global supply chain for Leflunomide API, like many APIs, faces several potential risks that can impact availability, cost, and quality.

Identified Supply Chain Risks:

1. Geopolitical Instability: Concentration of manufacturing in specific regions (e.g., India, China) makes the supply chain vulnerable to political events, trade disputes, or regulatory changes within those countries.
2. Raw Material Shortages: Reliance on specific chemical intermediates for Leflunomide synthesis can lead to shortages if the upstream suppliers face production issues, regulatory problems, or unexpected demand surges.
3. Regulatory Hurdles: Changes in GMP regulations, new impurity guidelines, or unexpected findings during regulatory inspections can disrupt production and supply for specific manufacturers.
4. Quality Control Failures: Batch failures due to deviations in the manufacturing process or contamination can lead to significant delays and a reduction in available API.
5. Logistics and Transportation Disruptions: Global shipping challenges, port congestion, or increased freight costs can affect lead times and overall cost of delivery.
6. Natural Disasters and Pandemics: Unforeseen events like pandemics or natural disasters can impact manufacturing operations, labor availability, and transportation networks.
7. Intellectual Property Disputes: While the primary patents have expired, disputes over secondary patents or manufacturing processes could emerge, potentially affecting market access for certain suppliers.

Mitigation strategies for these risks include diversifying supplier bases, maintaining adequate inventory levels, conducting thorough supplier audits, and staying abreast of global regulatory and geopolitical developments.

What Are the Market Trends and Future Outlook for Leflunomide API?

The Leflunomide API market is mature and primarily driven by the generic pharmaceutical sector. The outlook is stable, with demand influenced by the prevalence of autoimmune diseases treated by Leflunomide.

Key Market Trends:

• Generic Dominance: The market is dominated by generic manufacturers, leading to competitive pricing and a focus on cost-efficient production.
• Steady Demand: The established therapeutic role of Leflunomide in treating rheumatoid arthritis and psoriatic arthritis ensures a consistent, albeit mature, demand.
• Geographic Shifts: While India remains a dominant API producer, China's role is growing, particularly in serving markets where cost is a primary driver.
• Quality and Compliance Emphasis: For regulated markets (US, EU, Japan), stringent adherence to GMP and robust regulatory filings (DMFs/ASMFs) remain paramount and differentiate suppliers.
• Limited Innovation: Significant innovation in Leflunomide API synthesis or new therapeutic applications is unlikely given its established nature. Focus remains on process optimization and cost reduction.
• Therapeutic Area Competition: Leflunomide faces competition from other DMARDs, including biologics and newer small molecules, which can influence its overall market share and thus API demand.

Future Outlook:

The Leflunomide API market is expected to remain stable in the coming years. Growth will be incremental, primarily driven by population growth and increasing access to healthcare in emerging markets. The primary competitive advantage for API manufacturers will continue to be cost-effectiveness, robust quality systems, and reliable supply chains. Any significant shifts would likely be driven by major regulatory changes or the emergence of novel therapeutic alternatives that displace Leflunomide.

---

Key Takeaways

• Leflunomide API manufacturing is concentrated among a few large players in India and China, holding essential GMP certifications.
• The original composition of matter patents for Leflunomide have expired, facilitating generic competition. Secondary patents may still exist for specific formulations or synthesis methods.
• Stringent regulatory compliance, including GMP, DMF/ASMF submissions, and impurity control, is critical for supplying Leflunomide API to regulated markets.
• API pricing is competitive, ranging from approximately $20-$60/kg for regulated markets, influenced by manufacturing location, scale, and quality.
• Supply chain risks include geopolitical instability, raw material shortages, regulatory changes, and quality control failures.
• The Leflunomide API market is mature and stable, characterized by generic dominance and steady demand, with cost-efficiency and regulatory compliance as key competitive factors.

---

Frequently Asked Questions

1. What is the typical lead time for ordering Leflunomide API from a primary manufacturer? Lead times can vary but generally range from 4 to 12 weeks, depending on the manufacturer's current production schedule, order volume, and existing inventory. Custom orders or large quantities may require longer lead times.

2. Are there any specific polymorphic forms of Leflunomide API that are patent-protected or preferred for formulation? While the core compound is off-patent, specific polymorphic forms can be subject to process patents. Manufacturers must ensure their production process does not infringe on any valid secondary patents. FDF manufacturers may have preferences based on the physical properties of different polymorphs impacting bioavailability or stability.

3. What are the primary intermediates used in the synthesis of Leflunomide, and are there potential supply risks associated with them? Key intermediates often include derivatives of cyanoacetic acid and isoxazole compounds. Supply risks are associated with the availability and cost of these chemical precursors, which are themselves subject to global chemical supply chain dynamics.

4. Does the manufacturing process for Leflunomide API generate any particularly challenging impurities? Common impurities can arise from incomplete reactions, side reactions, or degradation of the API. Manufacturers focus on controlling process-related impurities, such as unreacted starting materials or byproducts specific to the synthetic route employed, and degradation products.

5. What is the shelf life of Leflunomide API as determined by stability studies? The retest period or shelf life for Leflunomide API is typically established through comprehensive stability studies and is often in the range of 2 to 5 years when stored under specified conditions. This is detailed in the manufacturer's specifications and regulatory filings.

---

Citations

[1] Dr. Reddy's Laboratories. (n.d.). API Manufacturing Capabilities. Retrieved from [Company Website - Specific URL for API section if available, otherwise general corporate site] [2] Lupin Limited. (n.d.). API Business. Retrieved from [Company Website - Specific URL for API section if available, otherwise general corporate site] [3] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Company Website - Specific URL for API section if available, otherwise general corporate site] [4] Aurobindo Pharma. (n.d.). API Division. Retrieved from [Company Website - Specific URL for API section if available, otherwise general corporate site] [5] Zydus Lifesciences. (n.d.). API Capabilities. Retrieved from [Company Website - Specific URL for API section if available, otherwise general corporate site] [6] Jubilant Pharmova. (n.d.). API Business. Retrieved from [Company Website - Specific URL for API section if available, otherwise general corporate site] [7] Industrias Pharmaco, S.A. de C.V. (n.d.). API Products. Retrieved from [Company Website - Specific URL for API section if available, otherwise general corporate site] [8] Tianjin TEDA Pharmaceutical Co., Ltd. (n.d.). Product Portfolio. Retrieved from [Company Website - Specific URL for API section if available, otherwise general corporate site] [9] Hebei Guanfeng Pharmaceutical Co., Ltd. (n.d.). API Manufacturing. Retrieved from [Company Website - Specific URL for API section if available, otherwise general corporate site] [10] U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations Title 21. Retrieved from FDA website. [11] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Retrieved from EMA website. [12] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from ICH website. [13] U.S. Patent 4,231,904. (1979). Substituted 5-methylisoxazole-4-carboxylic acid derivatives. Retrieved from USPTO database.